Journey Medical Corporation
DERMHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Journey Medical Corporation focuses on Drug Manufacturers - Specialty & Generic services and products. Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Valued at $197.1M, DERM is a micro-cap name in its sector. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Market Cap
$197.1M
Beta
1.07
P/E (TTM)
—
P/E (Fwd)
-119.33
EPS (TTM)
$-0.37
EPS (Fwd)
$-0.06
ROE
-36.6%
ROA
-4.5%
Cash
$27.2M
Total Debt
$25.5M
Free CF
-$3.3M
52W Change
-0.4%
Annual Financials
Cash vs Debt
With $27.2M in cash and $25.5M in debt, DERM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$3.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -36.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $73.7M to $61.9M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing DERM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.